Hearts & Minds Blog

Important Bempedoic Acid-Based Franchise Progress Updates

Tim Mayleben

President and Chief Executive Officer

Last week was exciting for us at Esperion as we reported on tremendous progress achieved in enrolling patients for our… more

The Bempedoic Acid / Ezetimibe Combo Pill: Our Leading Complementary, Non-statin, Oral Therapy

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

This week we announced a major milestone: the U.S. Food and Drug Administration (FDA) confirmed the regulatory pathway to approval… more

Setting the Record Straight: The Facts About Bempedoic Acid

Tim Mayleben

President and Chief Executive Officer

We recently became aware of comments published containing misinterpretations or intentionally inaccurate statements regarding Esperion and bempedoic acid.  As the… more

ACC Scientific Session Reflections: A Conversation Among Members of The Lipid Management Team

Tim Mayleben

President and Chief Executive Officer

Mary McGowan

Chief Medical Officer

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

Last week The Lipid Management team attended the American College of Cardiology (ACC) 66th Annual Scientific Session in Washington D.C…. more

Validating Our Approach: Dr. Ference to Present Results from Mendelian Randomization Studies of ACL Inhibition at the Upcoming ACC Scientific Session

Tim Mayleben

President and Chief Executive Officer

As a team of lipid management experts, we often “geek out” on the science behind LDL-cholesterol lowering therapies. That’s why… more